Introduction {#S1}
============

Lung cancer is the world's leading cause of cancer death,^[@R1]^ and non-small cell lung cancer (NSCLC) accounts for 80--85% of lung cancer cases. Cisplatin- or carboplatin-based combinations are generally used in metastatic NSCLC,^[@R2]^ and yield median survival times (MSTs) of 8--10 months.^[@R3]^ Platinum-based regimens are combined with radiotherapy for inoperable stage IIIA and IIIB NSCLC,^[@R4]^ with MSTs of 15--18 months,^[@R5]^ and adjuvant platinum-based chemotherapy increases 5-year survival rates by approximately 5% in patients with resected NSCLC, with the major benefit being seen in stages II and III.^[@R6]^

The Wingless-type protein (Wnt) signaling pathway helps maintain cancer stem cells,^[@R7]^ and signals through the major ("canonical") Wnt pathway via β-catenin and through various secondary ("non-canonical") pathways.^[@R7],[@R8]^ If Wnt is not present, β-catenin is phosphorylated by a complex consisting of Axis inhibition protein (AXIN), adenomatous polyposis coli (APC) and glycogen synthase kinase-3β (GSK-3β), and this phosphorylation results in its proteolytic degradation.^[@R8]^ If Wnt is present, it complexes with members of the Frizzled (FZD) family of receptors, lipoprotein receptor-related protein (LRP), Disheveled (Dvl) and AXIN,^[@R7],[@R8]^ thereby inhibiting GSK-3β and preventing β-catenin destruction.^[@R7],[@R8]^ β-catenin then migrates to the nucleus and complexes with members of T-cell factor (TCF)/Lymphoid enhancer-binding factor (LEF) family of transcription factors,^[@R8]^ and interacts with various transcriptional coactivators, such as cAMP response element-binding protein (CREB)-binding protein (CBP) or its homolog p300.^[@R8]^ This ultimately leads to expression of cyclin D1,^[@R7],[@R9]^ c-Myc,^[@R7]^ and other target genes.

There are also several Wnt inhibitors, including some members of the Wnt family itself (Wnt-5a and -5b),^[@R10]^ secreted frizzled-related proteins (sFRPs) ^[@R7]^, Wnt inhibitory factor-1 (WIF-1),^[@R7]^ Cerberus,^[@R7]^ Disabled-2 (Dab2),^[@R8]^ members of the Dickkopf (Dkk) family,^[@R7]^ and the Dvl antagonists Idax (coded by the *CXXC4* gene^[@R11]^) and human homolog of Dapper (HDPR1).^[@R12]^

In NSCLC cell lines and/or xenografts, Wnt pathway activation, overexpression of various Wnt pathway components or aberrant methylation or down-regulation of expression of Wnt pathway inhibitors is associated with increased cell proliferation or xenograft growth and with increased cellular motility and invasion.^[@R13]^ Similarly, in resected NSCLC tumor samples, Wnt pathway activation, overexpression of various Wnt pathway components or aberrant methylation or down-regulation of expression of Wnt pathway inhibitors is associated with poor prognosis.^[@R13]^ Wnt signaling may also be associated with resistance to cisplatin, docetaxel and radiation.^[@R13]^

Cancers "inherit" genes from the host, and host genotype single nucleotide polymorphisms (SNPs) can thereby affect tumor behavior. Across a range of malignancies, various Wnt pathway component SNPs or SNP interactions have correlated with risk of cancer development,^[@R14]--[@R16]^ or with tumor grade,^[@R17]^ stage,^[@R17]^ metastases,^[@R14]^ or prognosis.^[@R14],[@R18],[@R19]^ Exploration of the impact of Wnt pathway SNPs in NSCLC has to date been very limited.^[@R20]^ Because the Wnt pathway appears to be very important in NSCLC, and because Wnt signaling is associated with resistance to platinums in cell lines, we hypothesized that Wnt signaling pathway SNPs would correlate with survival of platinum-treated patients with stage III--IV NSCLC.

Methods {#S2}
-------

Patients for this study were from the University of Texas MD Anderson Cancer Center (MDACC) and from the Mayo Clinic, recruited according to protocols approved by the Institutional Review Boards of the two institutions. All patients gave written informed consent. From each patient, blood was drawn into heparinized tubes, and clinical, demographic, therapy and follow-up data were recorded.

Cohort 1 {#S3}
--------

We initially assessed 598 MDACC patients with inoperable stage III--IV NSCLC and no prior chemotherapy that were receiving platinum-based chemotherapy. Of these, 331 also received radiotherapy.

Cohorts 2--4 {#S4}
------------

In secondary analyses to assess whether our initial observations could be extrapolated to other NSCLC populations, we assessed 240 consenting Mayo Clinic patients receiving first line platinum-based chemotherapy alone (100 patients) or combined with radiotherapy (140 patients) for inoperable stage III (106 patients) or IV (134 patients) NSCLC (cohort 2). We also assessed 127 MDACC patients with resected NSCLC who received adjuvant platinum-based chemotherapy (cohort 3) and 340 MDACC patients undergoing surgical resection alone for NSCLC (cohort 4). The Mayo Clinic cohort was most similar to our initial cohort (metastatic NSCLC treated with platinum-based therapy). The adjuvant chemotherapy group was assessed based on the hypothesis that the impact of a specific SNP on chemotherapy efficacy or on prognosis might hold independent of tumor stage. The surgery alone group was assessed based on the hypothesis that if a SNP were a prognostic factor (linked to tumor aggressivenss) rather than a predictive factor (linked to chemotherapy sensitivity) then if might correlate with outcome even in patients who had not received any chemotherapy.

Polymorphism selection and genotyping {#S5}
-------------------------------------

For cohort 1, we utilized Gene Oncology (<http://www.geneontology.org>) and performed a literature search of the National Center for Biotechnology Information (NCBI) PubMed (<http://www.ncbi.nlm.nih.gov>) database to identify a list of Wnt pathway-related genes. A priority score was assigned to each gene based on its importance and relevance to cancer and to the Wnt signaling pathway. For each gene, we selected haplotype tagging SNPs (htSNPs) located within 10 kb upstream of the transcriptional start site and 10 kb downstream of the transcriptional stop site based on data from the International HapMap Project (<http://www.hapmap.org>). Using the LD select program (<http://droog.gs.washing.edu/ldSelect.html>) and the UCSC Golden Path Gene Sorter program (<http://genome.ucsc.edu>), we further divided identified SNPs into bins based on an r^2^ threshold of 0.8 and minor allele frequency (MAF) greater than 0.05 in Caucasians to select tagging SNPs. We also included potentially functional SNPs in the coding (synonymous SNPs, nonsynonymous SNPs) and regulatory regions (promoter, splicing site, 5-UTR, and 3-UTR). Selected SNPs were submitted to Illumina technical support for Infinium chemistry designability, beadtype analyses, and iSelect Infinium Beadchip synthesis. Due to limitation on the total number of SNPs that can be incorporated into the initial chip design, some genes of the Wnt pathway could not be included in this analysis (e.g. GSK3β, genes of noncanonical pathways, and downstream targets).

Genomic DNA was extracted from peripheral blood lymphocytes and stored at −80° C. Using the standard 3-day protocol for Illumina's Infinium iSelect HD Custom Genotyping BeadChip (Illumina, San Diego, CA) genotyping was successful in all 441 SNPs selected. BeadStudio software was used to autocall genotypes.

In cohorts 2--4, SNPs emerging as being most important in cohort 1 were then assessed using Taqman genotyping assay for Mayo Clinic patients and Illumina iSelect Infinium Beadchip for the MDACC adjuvant chemotherapy group and surgery alone group.

Statistical analysis {#S6}
--------------------

STATA software (version 10; STATA Corporation, College Station, TX) was used for statistical analyses. In cohort 1, Chi square test was used to assess differences between alive and dead patient groups for categorical variables in the host population. Cox's proportional hazards model was used to estimate Hazard Ratios (HRs) for the multivariate survival analyses, with adjustment for age, sex, ethnicity, smoking status, clinical stage, and performance status (PS). Kaplan-Meier curves were used to assess genotype effect on overall survival and log rank tests were used to assess survival differences across genotypes. The most common genotype served as the reference group. All statistical analyses were two sided. *P*\<0.05 was considered statistically significant. To correct for the effect of multiple comparisons, q values (false discovery rate adjusted *P*-values) were calculated by published methods^[@R21]^ implemented in the R package. SNPs with q\<0.10 were then used to assess the combined effects of unfavorable genotypes. Survival tree analysis was performed to assess higher-order gene-gene interactions using the STREE program (<http://masal.med.yale.edu/stree/>), which utilizes recursive-partitioning to identify subgroups of individuals with similar risk.

In cohorts 2--4, we assessed SNPs that were found to be important in cohort 1 and used multivariate Cox proportional hazards model to determine their association with outcome in each of cohorts 2--4 singly. Meta-analysis was conducted using HR and 95% CI derived from the Cox regression analysis in each of cohorts 2--4 to estimate the HR and 95% CI in cohorts 2--4 combined, and in the Mayo Clinic cohort (cohort 2) combined with the MDACC cohort that received adjuvant chemotherapy (cohort 3).

eQTL ANALYSIS {#S7}
=============

We checked for potential functional effects of identified SNPs on gene expression through the analysis of gene-SNP associations in expression quantitative trait loci (eQTL) studies compiled by the Genevar (GENe Expression VARiation) database (<http://www.sanger.ac.uk/resources/software/genevar/>)^[@R22]^ using the HapMap3 dataset, the seeQTL database (<http://www.bios.unc.edu/research/genomic_software/seeQTL/>),^[@R23]^ and the University of Chicago eQTL (<http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/>). All analyses were performed in the CEU population with MAF≥0.05.

Results {#S8}
=======

Characteristics of patients in cohort 1 are outlined in [Table 1](#T1){ref-type="table"}. Of the 441 SNPs assessed ([Table 2](#T2){ref-type="table"}), 57 were significantly associated with survival in multivariate analysis after adjusting for patients' age, ethnicity, pack-year smoking history, clinical stage, and performance status (p\<0.05, [Table 3](#T3){ref-type="table"}), including SNPs in *AXIN2* (9 SNPs), *LRP 5* (7 SNPs), *Wnt-5A* (4 SNPs), *AXIN1*, *LRP6*, *WIF1*, *Wnt-2*, *Wnt-4*, *Wnt-3* and *Wnt-5B* (3 SNPs each), *CXXC4*, *Wnt-3A*, *Wnt-7A*, *Wnt-9A* and *TLE2* (2 SNPs each), and *DVL3*, *FRZB*, *FZD4*, *Wnt-6*, *Wnt-9B* and *Wnt-11* (1 SNP each). None of the 5 SNPs assessed from the gene for β-catenin (*CTNNB1)* correlated with patient survival.

Of the 57 SNPs with p\<0.05, 5 had q\<0.10 after correction for multiple comparisons ([Table 4](#T4){ref-type="table"}). Compared to the reference genotypes, variants for rs11868547 and rs4541111 (both in *AXIN2*) were associated with improved survival, while variants for rs12819505 (*WNT5B*), rs4413407 (*CXXC4*) and rs10878232 (*WIF1*) were associated with worse survival after adjusting for clinical variables, as outlined above. MSTs were 19.7 months for patients with just one of these 5 unfavorable SNPs vs. 15.6 months for patients with 2 unfavorable SNPs and 10.7 months for patients with 3--5 unfavorable SNPs (p for trend 3.8 × 10^−9^, log rank p=1.86 × 10^−7^, [Table 5](#T5){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). Each of these SNPs remained significantly (p\<0.005) associated with survival after adjusting for agents (taxane vs other) given concurrently with cisplatin or carboplatin (data not shown). MAF of these SNPs by race is presented in [Table 6](#T6){ref-type="table"}.

For these 5 most significant SNPs, recursive partitioning STREE analysis ([Figure 2](#F2){ref-type="fig"}) indicated high order gene-gene interaction and divided patients into 5 distinct "nodes" with significant survival differences. These nodes could be further classified into two groups of low and high risk. Nodes 1 and 2 combined had significantly better survival than nodes 3, 4 and 5 combined (17.3 vs 11.3 months, log rank p=4.7 × 10^−8^, Wilcoxon p=1.0 × 10^−8^) ([Table 7](#T7){ref-type="table"} and [Fig 3](#F3){ref-type="fig"}). The 75^th^ percentile, 50^th^ percentile and 25^th^ percentile survival times were 7.4 months (95% CI 6.5--8.8 months), 16.2 (13.8--18.0) months and 32.2 (26.8--41.3) months, respectively, in the combined Nodes 1 and 2 group, and were 5.9 (4.6--7.1) months, 11.1 (9.6--11.9) months and 22.2 (18.4--26.3) months, respectively, in the combined Nodes 3, 4 and 5 group (log rank p=1.04 × 10^−4^, Wilcoxon p=5.87 × 10^−5^).

Characteristics of patients in Cohorts 2, 3 and 4 are presented in [Table 8](#T8){ref-type="table"}. Since there was high linkage disequilibrium between the two *AXIN2* SNPs s4341111 and rs11868547 (R^2^\>0.80), we only considered the one with the more significant p-value rs11868547 in the secondary analysis involving cohorts 2--4. None of the 4 SNPs assessed correlated significantly with survival in any of cohorts 2--4 assessed individually, nor in meta-analyses combining cohorts 2--4 together, nor in the meta-analysis combining cohort 2 (Mayo Clinic patients) with cohort 3 (MDACC adjuvant chemotherapy patients) ([Table 9](#T9){ref-type="table"}). However, for rs11868547, the hazard ratios for each of cohorts 2--4 and for the 2 meta-analyses was in the same direction as in cohort 1. For rs12819707, the hazard ratio for cohort 2 (the Mayo Clinic group), cohort 4 (the surgery alone group) and the overall meta-analysis of cohorts 2--4 was in the same direction as in cohort 1, and for rs10878232, the hazard ratio for two of the 3 secondary analysis cohorts and for both meta-analyses secondary analysis groupings was in the same direction as in cohort 1.

In assessing correlation of these SNPs with NSCLC stage across all 4 cohorts, we found that none of the SNPs were significantly associated with stage except for rs10878232 in cohort 4 (the surgery alone group) (p\<0.05).

To explore whether any of the 4 SNPs have functional relevance, we conducted expression quantitative trait loci (eQTL) analysis. We checked 3 databases including Genevar, seeQTL, and University of Chicago eQTL. Among candidate SNPs, a highly significant correlation was consistently shown for rs10878232 and *LEMD3*. Genevar analysis showed that the C allele was consistently correlated with higher expression of *LEMD3* in adipose tissues, lymphoblastoid cell lines and skin tissues obtained from healthy female twins ([Figure 4](#F4){ref-type="fig"}). All p-values are less than 10^−6^ for Spearman's correlation and \<10^−4^ for permutation test. Similar results were obtained by exploring the seeQTL and University of Chicago eQTL. rs10878232 is located in the 5′ flanking region between *WIF1* and *LEMD3*. No cis-eQTL correlation was found for the other SNPs.

Discussion {#S9}
==========

Results from our initial cohort suggested that selected host genotype Wnt pathway SNPs may affect outcome in platinum-treated patients with stage III--IV NSCLC: 57 SNPs in 21 different Wnt pathway components correlated with survival. Of these, 5 SNPs in 4 pathway genes remained significant in multivariate analysis after correcting for the effect of multiple comparisons and after adjusting for other clinical factors. Survival worsened as the number of unfavorable genotypes increased, revealing the joint effect of these SNPs. Survival tree analysis revealed potential higher order gene-gene interactions.

In our follow-up studies exploring impact of these SNPs in other patient groups, cohort 2 (from the Mayo Clinic) was most similar to our initial cohort (platinum-based chemotherapy +/− radiotherapy for stage III--IV NSCLC), although the Mayo Clinic patient population was smaller (only 240 patients). As with cohort 1, rs11868547 G to C allelic change in Mayo Clinic patients was associated with improved survival and rs12819505 A to G allelic change was associated with worse survival. This suggests that these associations in particular warrant further assessment, although these associations did not achieve statistical significance in the Mayo Clinic patients. The lack of statistical significance in the Mayo Clinic patients (and outcomes for rs4413407 and rs10878232) may have been due to a true lack of biological importance of these SNPs (with the association in cohort 1 being due to chance alone), or could instead have been related to low statistical power (due to relatively small patient numbers in the Mayo Clinic cohort) or impact of unappreciated differences in the patient populations or therapy details. It would also be worthwhile assessing whether these differences might be related to differences in second or third line therapy between the 2 groups. We did not have data available on therapy received following first line platinum-based regimens, and so cannot directly test this here, but it is possible that an association of the SNPs with survival could have been impacted by specific therapies received.

None of the SNPs correlated significantly with outcome in cohort 3 (the MDACC postoperative adjuvant chemotherapy NSCLC group) nor in cohort 4 (the MDACC surgery alone NSCLC group), indicating that we cannot extrapolate from our advanced disease patients to our early stage patients. Again, this may have been due to patient numbers/low statistical power or it could have been due to the differences that existed between the patient groups or to actual lack of biological importance of the SNPs identified in cohort 1.

When we did a meta-analysis adding cohorts 2--4 together, the direction of association (decreased risk for rs11868547 G to C allelic change and increased risk for rs12819505 A to G allelic change and rs10878232 A to C allelic change) was the same in the meta-analysis as in cohort 1, supporting further assessment of these SNPs, although the associations were again not statistically significant.

With respect to the SNPs that emerged as being most important in our initial cohort, each of *AXIN2*, *CXX4* and *WIF1* are potentially important in NSCLC as Wnt pathway inhibitors. *AXIN2* allelic loss is common in NSCLC*,*^[@R20]^ hypermethylation of *AXIN* is often seen in resected NSCLC tumor samples,^[@R24]^ risk of developing lung adenocarcinoma varies with the host genotype for codon 50 of *AXIN2,*^[@R20]^ and lung cancer cell line transfection with *AXIN* increased apoptosis, inhibited cell line proliferation, and decreased cell invasiveness.^[@R25]^

While *Wnt-5a* appears to be important in NSCLC, there is less information available on *Wnt-5b,* although *Wnt-5b* expression is upregulated by exposure of bronchial epithelium to cigarette smoke extract.^[@R26]^ Both Wnt-5a and Wnt-5b are non-canonical Wnts and may inhibit canonical Wnt signaling.^[@R10]^

The *CXXC4* gene codes for the Disheveled (Dvl) inhibitor Idax.^[@R11]^ While little is known about the role of *CXXC4* or Idax in NSCLC, Dvl is probably important. Dvl is frequently expressed in NSCLC tumor samples,^[@R27]^ and expression is associated with poor prognosis.^[@R28]^ In NSCLC cell lines, exogenous Dvl enhanced tumor cell invasiveness,^[@R27]^ and inhibition of Dvl inhibited growth.^[@R29]^

The Wnt pathway inhibitor *WIF-1* is frequently hypermethylated and/or down-regulated in NSCLC tumor samples and cell lines,^[@R30]--[@R32]^ particularly in squamous cell lung carcinomas^[@R31]^ and in patients with COPD,^[@R32]^ and promoter hypermethylation of *WIF-1* was associated with poor prognosis in NSCLC patients.^[@R32],[@R33]^ In lung cancer cell lines, methylation inhibitors^[@R34]^ or transfection with *WIF-1*^[@R35]^ demethylated *WIF-1*,^[@R34]^ increased *WIF-1* expression,^[@R34]^ inhibited the canonical Wnt pathway,^[@R34]^ inhibited cell line proliferation,^[@R35]^ and induced apoptosis.^[@R34],[@R35]^

Little is known regarding the functional impact of the SNPs observed. Further assessment of the functional impact would be useful in better understanding how these SNPs may have contributed to patient outcome and for validation in a larger independent cohort. None of the 5 most significant SNPs were in gene coding or promoter regions. While little is known about how these specific SNPs could affect gene/gene product functions, there are several possibilities. For example, SNPs in flanking regions may be in transcriptional enhancers that affect nearby gene expression,^[@R36]^ SNPs in the 3′ untranslated region (UTR) may affect microRNA binding^[@R37]^ and mRNA stability,^[@R38]^ nuclear transport,^[@R39]^ polyadenylation status^[@R39]^ and subcellular targeting,^[@R39]^ and intronic SNPs may affect alternative splicing^[@R40]^ and gene product function.^[@R41]^

To check for functional relevance for the identified SNPs from cohort 1, we carried out eQTL analysis using Genevar database (a public resource containing four eQTL studies^[@R42]--[@R45]^), and found highly significant correlation between rs10878232 and *LEMD3* expression. The rs10878232 data are available in the MuTHER pilot study implemented in Genevar. *LEMD3* (also known as *MAN1*) encodes a LEM domain-containing gene that serves to antagonize transforming growth factor beta signaling at the inner nuclear membrane.^[@R46]^ Mutations of this gene have been found in osteopoikilosis, Buscheke-Ollendorff syndrome, and melorheostosis.^[@R47]^ Interestingly, the expression level of *LEMD3* correlated with two loci associated with overall survival in never smokers with NSCLC in a previous study from our group.^[@R48]^ Although our current dataset of late-stage NSCLC patient is too small for stratified analysis by smoking status, we found a stronger association of rs10878232 with survival in never smokers while weak or no significant association was found in ever smokers, suggesting a potential interaction of this SNP with smoking status. In light of the known association of negative smoking history with epidermal growth factor (EGFR) mutations, one might question whether there might be an interaction of rs10878232 with EGFR mutation status, but this cannot be addressed in our study since EGFR mutation status was not known for most patients. Further study in a larger population of NSCLC patients is necessary to verify our findings and to assess any potential interaction with EGFR mutation status.

In summary, the pharmacogenetic data from our initial patient cohort suggest that host genotype SNPs may modulate the impact of the Wnt pathway on outcome of patients with advanced NSCLC, although SNP associations with outcome in secondary analyses using cohorts 2--4 were much weaker. Overall, available evidence from cell lines and resected tumors suggests that Wnt pathway signaling is important in NSCLC tumorigenesis, patient prognosis and resistance to therapy.^[@R13]^ Targeting of the Wnt pathway (through Wnt antagonists, demethylating agents, and other steps to restore function of silenced Wnt inhibitors) warrants assessment in the treatment of NSCLC.
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![Kaplan Meier survival estimates for patients with 1 (blue line) vs 2 (red line) vs 3--5 (green line) unfavorable genotypes (UFGs) in our initial cohort (median survival times 19.7 vs 15.7 vs 10.7 months, p for trend = 3.8 × 10^−9^, log rank p = 1.9 × 10^−7^)](nihms586716f1){#F1}

![Survival tree analysis of significant SNPs associated with NSCLC survival identified from the single SNP analysis (q\<0.10) in our initial cohort. Five terminal nodes were identified, which could be classified into two groups of low and high risk.](nihms586716f2){#F2}

![Kaplan Meier survival estimates for the two risk groups identified from the survival tree analysis of our initial cohort. Survival of NSCLC patients in STREE groups 1 (49 patients) and 2 (275 patients) (blue line) was significantly better than for groups 3 (198 patients), 4 (45 patients) and 5 (31 patients) combined (red line) (17.3 vs 11.1 months, Wilcoxon p=1.0 × 10^−8^, log rank p = 4.66 × 10^−8^).](nihms586716f3){#F3}

![Rs10878232 genotypes and *LEMD3* gene expression in cell lines and tissues from healthy female twins based on eQTL analysis in Genevar database of SNP-gene associations. Twin2-A, adipose tissue; Twin2-L, lymphoblastoid cell lines; Twin2-S, skin tissue. Rho, correlation value; Pemp, non-parametric permutation p value for 10,000 reiterations.](nihms586716f4){#F4}

###### 

Characteristics of 598 patients assessed in cohort 1

  Variable                                                   No. Patients (%)
  ---------------------------------------------------------- ------------------
  Median survival, months                                    12.9
  Median age (range), years                                  61 (28--81)
  Pack year, mean (SD)                                       45 (27.8)
  Survival status at last follow-up                          
   Alive                                                     142 (23.7)
   Dead                                                      456 (76.3)
  Sex                                                        
   Male                                                      323 (54.0)
   Female                                                    275 (46.0)
  Clinical stage                                             
   Stage IIIA                                                82 (13.7)
   Stage IIIB                                                
    No malignant effusion                                    142 (23.7)
    Malignant effusion[\*](#TFN1){ref-type="table-fn"}       39 (6.5)
   Stage IV                                                  335 (56.0)
  Smoking status                                             
   Never                                                     112 (18.7)
   Former                                                    243 (40.6)
   Current & Recently Quit (\<1 year)                        243 (40.6)
  ECOG Performance status                                    
   0                                                         143 (23.9)
   1                                                         334 (55.9)
   2--4                                                      74 (12.4)
   Unspecified                                               47 (7.9)
  Differentiation                                            
   Well                                                      27 (4.5)
   Moderate                                                  61 (10.2)
   Poor and undifferentiated                                 299 (50.0)
   Unspecified                                               211 (35.3)
  Weight loss                                                
   Weight gain or stable                                     295 (49.3)
   0--5%                                                     80 (13.4)
   5--10%                                                    88 (14.7)
   \>10%                                                     63 (10.5)
   Unknown                                                   72 (12.0)
  Race                                                       
   White                                                     470 (78.6)
   Black                                                     95 (15.9)
   Others                                                    33 (5.5)
  First line chemo agents (331 also received radiotherapy)   
   Platinum (cisplatin or carboplatin) only                  11 (1.8)
   Platinum + pemetrexed                                     21 (3.5)
   Platinum + etoposide +/− targretin                        88 (14.7)
   Platinum + gemcitabine +/− other agent                    25 (4.2)
   Platinum + taxane                                         283 (47.3)
   Platinum + taxane + other agents                          138 (23.1)
   Platinum + other agents                                   32 (5.4)

Now considered stage IV per recent revisions to staging systems^[@R49]^

SD- standard deviation

###### 

Wnt pathway SNPs that were assessed in cohort 1

  SNP          *P* value   Hazard Ratio (95% CI)   Gene       Chromo-some   Position    Q value
  ------------ ----------- ----------------------- ---------- ------------- ----------- -------------
  rs1882619    2.69E-01    0.85( 0.64--1.13)       *APC*      5             112106681   0.307820239
  rs2439595    2.21E-01    1.23( 0.88--1.72)       *APC*      5             112146237   0.290363518
  rs2431507    2.32E-01    0.86( 0.67--1.10)       *APC*      5             112174080   0.296677764
  rs2707761    6.88E-01    0.96( 0.77--1.19)       *APC*      5             112177826   0.424838822
  rs13167522   8.11E-01    1.03( 0.78--1.36)       *APC*      5             112195207   0.447606546
  rs42427      2.35E-01    1.18( 0.90--1.55)       *APC*      5             112204224   0.298902339
  rs459552     7.19E-02    1.49( 0.96--2.31)       *APC*      5             112204655   0.222980247
  rs2229995    8.78E-01    0.95( 0.52--1.75)       *APC*      5             112206694   0.468410227
  rs41116      8.13E-01    0.97( 0.78--1.21)       *APC*      5             112208820   0.447606546
  rs382427     7.86E-01    1.03( 0.82--1.30)       *APC*      5             112215335   0.443413702
  rs4807928    9.96E-02    1.18( 0.97--1.43)       *APC2*     19            1399180     0.247221759
  rs12005      3.11E-01    0.87( 0.67--1.14)       *APC2*     19            1408875     0.315893774
  rs11668593   6.94E-01    1.04( 0.84--1.29)       *APC2*     19            1411473     0.424838822
  rs265274     2.13E-01    1.20( 0.90--1.61)       *APC2*     19            1423007     0.284945038
  rs2456163    9.50E-02    1.29( 0.96--1.75)       *APC2*     19            1427432     0.246983910
  rs2238371    1.09E-01    0.66( 0.40--1.10)       *AXIN1*    16            268917      0.247221759
  rs373271     7.52E-01    0.95( 0.72--1.27)       *AXIN1*    16            269672      0.437337077
  rs421195     5.30E-01    0.92( 0.71--1.19)       *AXIN1*    16            273147      0.379736909
  rs419949     2.74E-01    1.12( 0.91--1.37)       *AXIN1*    16            274891      0.308381238
  rs2685127    4.14E-01    1.10( 0.88--1.37)       *AXIN1*    16            275374      0.354708008
  rs400037     2.15E-01    0.78( 0.52--1.16)       *AXIN1*    16            276397      0.284945038
  rs1048786    5.99E-02    1.25( 0.99--1.59)       *AXIN1*    16            276917      0.205417788
  rs394128     2.99E-01    0.82( 0.56--1.19)       *AXIN1*    16            277872      0.315893774
  rs214247     2.12E-01    1.14( 0.93--1.42)       *AXIN1*    16            289222      0.284945038
  rs214246     4.03E-02    0.77( 0.61--0.99)       *AXIN1*    16            289294      0.186192568
  rs1204042    1.48E-01    0.73( 0.47--1.12)       *AXIN1*    16            292737      0.270394908
  rs1981492    1.06E-01    1.19( 0.96--1.47)       *AXIN1*    16            296690      0.247221759
  rs11644916   6.02E-01    1.05( 0.87--1.28)       *AXIN1*    16            299568      0.401557037
  rs2301522    1.32E-01    0.77( 0.55--1.08)       *AXIN1*    16            299954      0.263342145
  rs17136060   8.74E-02    1.22( 0.97--1.52)       *AXIN1*    16            302460      0.244482539
  rs7359414    3.73E-02    0.78( 0.61--0.99)       *AXIN1*    16            302639      0.186192568
  rs3916990    2.89E-01    1.11( 0.91--1.36)       *AXIN1*    16            312598      0.314961177
  rs9921222    9.50E-01    1.00( 0.87--1.14)       *AXIN1*    16            315783      0.481138076
  rs12719801   7.19E-01    1.04( 0.85--1.27)       *AXIN1*    16            321142      0.426451944
  rs370681     7.03E-01    1.04( 0.84--1.30)       *AXIN1*    16            332462      0.426046532
  rs395901     5.33E-02    0.77( 0.59--1.00)       *AXIN1*    16            333343      0.196213611
  rs2885415    3.12E-01    1.11( 0.91--1.35)       *AXIN1*    16            335397      0.315893774
  rs758033     2.00E-01    1.14( 0.93--1.39)       *AXIN1*    16            337045      0.284431004
  rs12599449   6.14E-02    1.26( 0.99--1.60)       *AXIN1*    16            337270      0.205417788
  rs11645554   7.90E-02    0.71( 0.49--1.04)       *AXIN1*    16            340246      0.235767882
  rs17136255   1.99E-01    1.15( 0.93--1.43)       *AXIN1*    16            340476      0.284431004
  rs11860497   7.27E-02    1.21( 0.98--1.49)       *AXIN1*    16            345417      0.222980247
  rs9888749    3.11E-02    0.76( 0.60--0.98)       *AXIN1*    16            348373      0.185653186
  rs4340364    5.00E-01    1.08( 0.86--1.37)       *AXIN2*    17            60946245    0.377760052
  rs8068404    8.90E-02    0.61( 0.34--1.08)       *AXIN2*    17            60946802    0.245844226
  rs12452196   8.52E-01    0.98( 0.78--1.23)       *AXIN2*    17            60951241    0.458967631
  rs11868547   6.10E-04    0.77( 0.66--0.89)       *AXIN2*    17            60954065    0.095030240
  rs7591       6.14E-03    1.23( 1.06--1.44)       *AXIN2*    17            60955544    0.135500153
  rs4074947    4.68E-02    1.23( 1.00--1.51)       *AXIN2*    17            60957682    0.186667333
  rs7224837    3.44E-02    1.28( 1.02--1.62)       *AXIN2*    17            60958585    0.186192568
  rs11655966   1.48E-02    1.21( 1.04--1.41)       *AXIN2*    17            60960112    0.144627899
  rs4541111    1.53E-03    0.79( 0.68--0.91)       *AXIN2*    17            60965000    0.095030240
  rs11079571   1.62E-02    1.29( 1.05--1.59)       *AXIN2*    17            60979143    0.144627899
  rs3923087    5.29E-02    1.24( 1.00--1.53)       *AXIN2*    17            60979723    0.196213611
  rs3923086    1.06E-01    1.13( 0.97--1.32)       *AXIN2*    17            60979950    0.247221759
  rs757558     3.67E-01    1.11( 0.88--1.40)       *AXIN2*    17            60992054    0.331747799
  rs740026     4.46E-01    0.94( 0.81--1.10)       *AXIN2*    17            60992143    0.359705483
  rs12943295   4.39E-01    1.09( 0.88--1.36)       *AXIN2*    17            60994967    0.359395383
  rs1548581    3.65E-02    1.29( 1.02--1.64)       *AXIN2*    17            60995973    0.186192568
  rs1544427    3.39E-01    1.11( 0.89--1.39)       *AXIN2*    17            60996130    0.328827360
  rs2158520    9.29E-01    1.02( 0.68--1.52)       *AXIN2*    17            60996372    0.478174891
  rs12942924   1.57E-02    1.18( 1.03--1.36)       *AXIN2*    17            60996861    0.144627899
  rs9675157    6.67E-01    0.94( 0.69--1.26)       *AXIN2*    17            60997479    0.422148501
  rs2007085    8.21E-01    1.03( 0.80--1.33)       *AXIN2*    17            60997824    0.449815441
  rs17207681   4.58E-01    0.90( 0.69--1.18)       *CTN1*     5             138196426   0.359705483
  rs11744283   5.42E-01    1.13( 0.76--1.70)       *CTN1*     5             138237303   0.379736909
  rs288030     3.79E-01    1.09( 0.90--1.33)       *CTN1*     5             138244182   0.336074710
  rs288029     6.80E-01    1.04( 0.86--1.27)       *CTN1*     5             138245204   0.424838822
  rs10515503   7.80E-01    0.96( 0.73--1.27)       *CTN1*     5             138246077   0.443413702
  rs288027     6.15E-01    1.06( 0.85--1.33)       *CTN1*     5             138250229   0.407840284
  rs17031      6.17E-01    1.09( 0.77--1.55)       *CTN1*     5             138298441   0.407981867
  rs9872276    2.10E-01    0.86( 0.68--1.09)       *CTNNB1*   3             41206972    0.284945038
  rs1722846    1.39E-01    0.90( 0.79--1.03)       *CTNNB1*   3             41208893    0.265029247
  rs11564445   7.73E-01    1.06( 0.73--1.52)       *CTNNB1*   3             41242756    0.443413702
  rs11564447   1.04E-01    1.33( 0.94--1.89)       *CTNNB1*   3             41243358    0.247221759
  rs4135385    9.28E-01    1.01( 0.82--1.24)       *CTNNB1*   3             41254444    0.478174891
  rs4413407    1.72E-03    1.28( 1.10--1.50)       *CXXC4*    4             105612810   0.095030240
  rs4698921    4.04E-02    1.16( 1.01--1.34)       *CXXC4*    4             105633671   0.186192568
  rs10891310   2.49E-01    1.13( 0.92--1.38)       *DIXDC1*   11            111397269   0.301906315
  rs7100461    9.92E-02    0.77( 0.56--1.05)       *DKK1*     10            53735827    0.247221759
  rs1896368    3.19E-01    1.08( 0.93--1.25)       *DKK1*     10            53738910    0.317400735
  rs1528877    4.64E-01    1.09( 0.87--1.37)       *DKK1*     10            53741348    0.359830407
  rs3763511    5.40E-01    0.92( 0.69--1.21)       *DKK4*     8             42355015    0.379736909
  rs222850     2.78E-01    1.18( 0.88--1.58)       *DVL2*     17            7078674     0.310012797
  rs11919795   1.75E-02    0.67( 0.48--0.93)       *DVL3*     3             185373562   0.144627899
  rs4666865    5.64E-01    1.09( 0.81--1.46)       *FRZB*     2             183406336   0.388647584
  rs7775       8.96E-01    1.02( 0.79--1.31)       *FRZB*     2             183407829   0.474806202
  rs288326     8.17E-01    1.03( 0.81--1.31)       *FRZB*     2             183411581   0.448878241
  rs12469777   1.44E-02    0.85( 0.74--0.97)       *FRZB*     2             183440609   0.144627899
  rs506197     4.59E-01    0.95( 0.83--1.09)       *FSHB*     11            30212399    0.359705483
  rs506306     4.59E-01    0.95( 0.83--1.09)       *FSHB*     11            30212443    0.359705483
  rs676349     4.59E-01    0.95( 0.83--1.09)       *FSHB*     11            30212558    0.359705483
  rs560078     5.44E-01    0.96( 0.83--1.10)       *FSHB*     11            30213698    0.379736909
  rs12577729   2.10E-01    1.14( 0.93--1.41)       *FSHB*     11            30213953    0.284945038
  rs626869     4.59E-01    0.95( 0.83--1.09)       *FSHB*     11            30215346    0.359705483
  rs12537425   7.40E-01    1.03( 0.88--1.20)       *FZD1*     7             90726006    0.433519176
  rs6977978    9.40E-01    1.01( 0.81--1.25)       *FZD1*     7             90726349    0.478174891
  rs3750145    6.09E-01    0.94( 0.75--1.18)       *FZD1*     7             90734767    0.405077519
  rs10252817   4.56E-01    0.92( 0.74--1.14)       *FZD1*     7             90742874    0.359705483
  rs17163759   1.56E-01    0.81( 0.61--1.08)       *FZD1*     7             90744979    0.270394908
  rs4792948    1.61E-01    0.84( 0.66--1.07)       *FZD2*     17            39993014    0.271874053
  rs4793121    7.20E-01    0.96( 0.75--1.22)       *FZD2*     17            39993435    0.426451944
  rs7501777    2.43E-01    0.88( 0.72--1.09)       *FZD2*     17            39994203    0.301906315
  rs1946583    5.10E-01    1.08( 0.87--1.34)       *FZD3*     8             28406672    0.377760052
  rs352222     5.12E-01    1.07( 0.87--1.32)       *FZD3*     8             28477700    0.377760052
  rs4732863    4.32E-01    0.91( 0.72--1.15)       *FZD3*     8             28478407    0.359395383
  rs713065     1.99E-02    0.79( 0.64--0.96)       *FZD4*     11            86335168    0.146727575
  rs10898563   1.96E-01    1.22( 0.90--1.67)       *FZD4*     11            86336861    0.284431004
  rs13020497   3.57E-01    0.84( 0.59--1.21)       *FZD7*     2             202605764   0.328827360
  rs12994568   3.57E-01    0.84( 0.59--1.21)       *FZD7*     2             202605821   0.328827360
  rs13034206   3.57E-01    0.84( 0.59--1.21)       *FZD7*     2             202609480   0.328827360
  rs13034579   3.57E-01    0.84( 0.59--1.21)       *FZD7*     2             202609524   0.328827360
  rs4673222    3.39E-01    0.88( 0.68--1.14)       *FZD7*     2             202610155   0.328827360
  rs12474408   3.57E-01    0.84( 0.59--1.21)       *FZD7*     2             202612051   0.328827360
  rs12478708   3.57E-01    0.84( 0.59--1.21)       *FZD7*     2             202612343   0.328827360
  rs7583130    2.26E-01    0.85( 0.66--1.10)       *FZD7*     2             202613333   0.295085709
  rs1178947    2.83E-01    0.90( 0.73--1.10)       *FZD9*     7             72488114    0.312911216
  rs1046890    9.10E-01    0.99( 0.81--1.21)       *FZD10*    12            129215723   0.475872051
  rs3741568    7.88E-01    1.03( 0.84--1.26)       *FZD10*    12            129215915   0.443413702
  rs1046895    8.96E-01    0.99( 0.80--1.22)       *FZD10*    12            129215994   0.474806202
  rs11060753   7.88E-01    1.03( 0.84--1.26)       *FZD10*    12            129216375   0.443413702
  rs1463865    3.43E-01    0.83( 0.57--1.22)       *FZD10*    12            129217207   0.328827360
  rs11725638   3.18E-01    0.84( 0.59--1.18)       *LEF1*     4             109185967   0.317400735
  rs4245927    3.71E-01    1.22( 0.79--1.86)       *LEF1*     4             109189039   0.333220288
  rs17439845   9.12E-01    1.01( 0.78--1.32)       *LEF1*     4             109213028   0.475872051
  rs1291490    7.12E-01    0.96( 0.76--1.21)       *LEF1*     4             109213461   0.426046532
  rs4956157    7.09E-02    1.40( 0.97--2.02)       *LEF1*     4             109218815   0.222980247
  rs6533348    5.71E-02    1.34( 0.99--1.81)       *LEF1*     4             109236385   0.203076161
  rs749414     4.98E-01    0.94( 0.80--1.12)       *LEF1*     4             109247362   0.377760052
  rs7698367    1.35E-01    0.85( 0.70--1.05)       *LEF1*     4             109249931   0.263342145
  rs10022956   1.25E-01    0.86( 0.70--1.04)       *LEF1*     4             109253428   0.258797750
  rs10516550   5.68E-01    0.92( 0.69--1.22)       *LEF1*     4             109255277   0.388647584
  rs17038617   2.49E-01    0.88( 0.70--1.10)       *LEF1*     4             109266333   0.301906315
  rs12503104   4.62E-01    1.08( 0.88--1.34)       *LEF1*     4             109281959   0.359830407
  rs922163     6.86E-01    0.94( 0.71--1.25)       *LEF1*     4             109285815   0.424838822
  rs64388      3.31E-02    1.25( 1.02--1.52)       *LRP5*     11            67830957    0.186192568
  rs312009     1.12E-01    1.18( 0.96--1.45)       *LRP5*     11            67833814    0.247221759
  rs682429     1.13E-01    1.18( 0.96--1.44)       *LRP5*     11            67835895    0.247221759
  rs11228202   9.82E-01    1.00( 0.79--1.28)       *LRP5*     11            67840804    0.494069355
  rs4988331    2.40E-01    0.84( 0.63--1.12)       *LRP5*     11            67841909    0.301281403
  rs4988300    9.77E-03    0.74( 0.58--0.93)       *LRP5*     11            67845407    0.135500153
  rs2508836    1.03E-02    0.81( 0.68--0.95)       *LRP5*     11            67847841    0.135500153
  rs3781600    9.41E-01    0.99( 0.76--1.28)       *LRP5*     11            67849913    0.478174891
  rs606989     5.71E-01    1.08( 0.82--1.42)       *LRP5*     11            67858576    0.389104323
  rs312778     6.07E-02    0.78( 0.59--1.01)       *LRP5*     11            67864908    0.205417788
  rs314756     1.97E-02    0.69( 0.51--0.94)       *LRP5*     11            67868248    0.146727575
  rs729635     3.14E-01    0.87( 0.67--1.14)       *LRP5*     11            67868336    0.316902816
  rs312786     3.81E-02    0.66( 0.45--0.98)       *LRP5*     11            67876553    0.186192568
  rs624947     7.84E-01    1.02( 0.88--1.19)       *LRP5*     11            67897358    0.443413702
  rs638051     3.03E-01    1.14( 0.89--1.46)       *LRP5*     11            67897990    0.315893774
  rs11826287   4.64E-01    1.08( 0.88--1.33)       *LRP5*     11            67903237    0.359830407
  rs671191     3.61E-01    1.14( 0.86--1.51)       *LRP5*     11            67906557    0.328827360
  rs4930573    3.19E-01    0.84( 0.59--1.19)       *LRP5*     11            67920032    0.317400735
  rs545382     2.06E-01    0.85( 0.67--1.09)       *LRP5*     11            67927589    0.284431004
  rs2277268    4.67E-01    0.90( 0.68--1.20)       *LRP5*     11            67930698    0.360602406
  rs640569     4.14E-01    0.86( 0.61--1.23)       *LRP5*     11            67941396    0.354708008
  rs608343     9.14E-01    1.01( 0.83--1.24)       *LRP5*     11            67953406    0.475872051
  rs3781586    4.47E-02    1.26( 1.01--1.57)       *LRP5*     11            67955969    0.186200636
  rs12417014   5.18E-01    0.92( 0.70--1.20)       *LRP5*     11            67957583    0.379094638
  rs2242340    5.10E-01    0.92( 0.71--1.19)       *LRP5*     11            67970695    0.377760052
  rs676318     4.18E-02    0.75( 0.57--0.99)       *LRP5*     11            67973996    0.186192568
  rs2302684    1.14E-01    0.84( 0.68--1.04)       *LRP6*     12            12169735    0.247221759
  rs1012672    1.09E-02    1.47( 1.09--1.97)       *LRP6*     12            12176182    0.135500153
  rs11054704   9.12E-01    0.99( 0.78--1.25)       *LRP6*     12            12191036    0.475872051
  rs2302685    5.05E-01    0.93( 0.75--1.15)       *LRP6*     12            12193165    0.377760052
  rs11054709   2.00E-01    0.84( 0.65--1.10)       *LRP6*     12            12193689    0.284431004
  rs7301012    3.00E-01    1.12( 0.90--1.39)       *LRP6*     12            12198911    0.315893774
  rs12310020   1.58E-01    0.83( 0.64--1.08)       *LRP6*     12            12212448    0.270394908
  rs12833575   7.44E-01    0.95( 0.68--1.32)       *LRP6*     12            12216108    0.434472104
  rs11054721   1.37E-01    1.19( 0.95--1.49)       *LRP6*     12            12222594    0.263578639
  rs10845493   4.39E-01    1.09( 0.87--1.37)       *LRP6*     12            12223463    0.359395383
  rs10492120   6.94E-01    1.04( 0.85--1.28)       *LRP6*     12            12224619    0.424838822
  rs10845498   7.58E-01    0.97( 0.78--1.20)       *LRP6*     12            12285841    0.437484457
  rs12823867   7.93E-01    1.03( 0.83--1.27)       *LRP6*     12            12287397    0.443989861
  rs10743980   5.74E-02    1.15( 1.00--1.32)       *LRP6*     12            12304062    0.203076161
  rs12309338   6.00E-01    0.93( 0.71--1.22)       *LRP6*     12            12312326    0.401557037
  rs7136900    5.61E-01    1.04( 0.90--1.21)       *LRP6*     12            12314360    0.388164447
  rs12816278   9.69E-01    1.00( 0.80--1.25)       *LRP6*     12            12317344    0.488452597
  rs7296283    2.57E-01    1.10( 0.93--1.31)       *LRP6*     12            12319275    0.302073322
  rs11054760   1.67E-02    1.53( 1.08--2.17)       *LRP6*     12            12320749    0.144627899
  rs10431302   4.21E-02    0.80( 0.65--0.99)       *LRP6*     12            12320918    0.186192568
  rs10491321   9.39E-01    1.01( 0.82--1.24)       *PPP2CA*   5             133555489   0.478174891
  rs4246019    6.39E-01    0.94( 0.74--1.20)       *PPP2CA*   5             133593991   0.414986215
  rs254057     5.79E-02    1.26( 0.99--1.60)       *PPP2CA*   5             133599755   0.203076161
  rs6993129    6.45E-01    0.95( 0.77--1.18)       *PPP2CB*   8             30753679    0.415574805
  rs7017734    6.45E-01    0.95( 0.77--1.18)       *PPP2CB*   8             30754985    0.415574805
  rs11780378   6.93E-01    1.06( 0.80--1.39)       *PPP2CB*   8             30760201    0.424838822
  rs4733509    8.33E-01    1.04( 0.74--1.46)       *PPP2CB*   8             30761490    0.452520518
  rs13268487   9.84E-01    1.00( 0.73--1.38)       *PPP2CB*   8             30766081    0.494172410
  rs1116003    9.46E-02    1.39( 0.94--2.04)       *PPP2CB*   8             30774905    0.246983910
  rs4733200    5.92E-01    1.08( 0.81--1.45)       *PPP2CB*   8             30784198    0.397139194
  rs4733518    5.92E-01    1.08( 0.81--1.45)       *PPP2CB*   8             30793453    0.397139194
  rs2248033    5.18E-02    0.82( 0.67--1.00)       *PYGO1*    15            53619722    0.196213611
  rs1624779    6.98E-02    0.83( 0.68--1.01)       *PYGO1*    15            53620813    0.222980247
  rs16976371   9.05E-01    1.02( 0.79--1.30)       *PYGO1*    15            53624141    0.475872051
  rs11071189   1.98E-01    1.16( 0.93--1.45)       *PYGO1*    15            53624380    0.284431004
  rs11858624   6.54E-01    0.93( 0.67--1.28)       *PYGO1*    15            53625877    0.418665386
  rs7183943    7.79E-02    0.84( 0.69--1.02)       *PYGO1*    15            53662358    0.235608553
  rs7181481    4.50E-01    1.10( 0.86--1.41)       *PYGO1*    15            53674236    0.359705483
  rs7181496    7.52E-01    0.97( 0.79--1.18)       *PYGO1*    15            53674260    0.437337077
  rs12898968   5.39E-01    0.93( 0.73--1.18)       *PYGO1*    15            53674548    0.379736909
  rs2917844    7.31E-01    0.96( 0.75--1.22)       *PYGO1*    15            53675019    0.431489740
  rs552292     6.84E-01    0.97( 0.84--1.12)       *PYGO1*    15            53676324    0.424838822
  rs6474328    2.94E-01    1.11( 0.91--1.36)       *SFRP1*    8             41236656    0.315417003
  rs3242       3.12E-01    1.08( 0.93--1.26)       *SFRP1*    8             41238711    0.315893774
  rs12914      3.10E-01    1.11( 0.91--1.36)       *SFRP1*    8             41239309    0.315893774
  rs1127379    2.93E-01    1.14( 0.89--1.46)       *SFRP1*    8             41240437    0.315417003
  rs12639885   6.31E-01    1.05( 0.86--1.29)       *SFRP2*    4             154919824   0.413471411
  rs10014299   6.37E-01    1.05( 0.85--1.29)       *SFRP2*    4             154920308   0.414986215
  rs2039826    7.59E-01    0.95( 0.70--1.30)       *SFRP5*    10            99516658    0.437484457
  rs7478323    7.57E-01    0.95( 0.70--1.30)       *SFRP5*    10            99516933    0.437484457
  rs4919139    5.02E-01    1.07( 0.87--1.32)       *SFRP5*    10            99522850    0.377760052
  rs168649     5.66E-01    1.07( 0.86--1.32)       *TCF7*     5             133472819   0.388647584
  rs244952     4.18E-01    0.89( 0.66--1.19)       *TCF7*     5             133474171   0.354708008
  rs2436323    4.18E-01    0.89( 0.66--1.19)       *TCF7*     5             133474960   0.354708008
  rs151822     6.55E-01    1.05( 0.85--1.29)       *TCF7*     5             133483860   0.418665386
  rs152402     1.92E-01    1.15( 0.93--1.43)       *TCF7*     5             133506240   0.284431004
  rs30489      8.72E-01    0.98( 0.75--1.28)       *TCF7*     5             133509366   0.466081299
  rs4958216    1.13E-01    1.19( 0.96--1.48)       *TCF7*     5             133514162   0.247221759
  rs390258     4.64E-03    1.64( 1.16--2.30)       *TLE2*     19            2947339     0.128006452
  rs423232     2.21E-02    0.74( 0.57--0.96)       *TLE2*     19            2947483     0.152312051
  rs4806893    1.04E-01    0.81( 0.63--1.04)       *TLE2*     19            2947889     0.247221759
  rs14089      7.35E-01    0.96( 0.75--1.22)       *TLE2*     19            2948790     0.432545906
  rs1688128    7.36E-01    1.04( 0.83--1.30)       *TLE2*     19            2981168     0.432545906
  rs3743309    1.72E-01    1.19( 0.93--1.51)       *TLE3*     15            68127565    0.277576313
  rs2807304    4.23E-01    0.94( 0.79--1.10)       *TLE4*     9             81375174    0.357966724
  rs4355856    9.34E-01    1.01( 0.82--1.24)       *TLE4*     9             81532323    0.478174891
  rs4285553    9.34E-01    1.01( 0.82--1.24)       *TLE4*     9             81532471    0.478174891
  rs11667371   4.00E-01    0.83( 0.54--1.28)       *TLE6*     19            2927724     0.349296428
  rs17681742   4.11E-01    1.10( 0.88--1.37)       *TLE6*     19            2928599     0.354708008
  rs1446527    2.87E-01    0.87( 0.68--1.12)       *WIF1*     12            63733304    0.313365199
  rs3782497    6.73E-01    0.93( 0.68--1.28)       *WIF1*     12            63746341    0.423223626
  rs3782499    3.07E-01    1.16( 0.87--1.55)       *WIF1*     12            63752919    0.315893774
  rs6581606    1.24E-01    1.12( 0.97--1.30)       *WIF1*     12            63753893    0.258519177
  rs12818732   3.02E-01    1.21( 0.84--1.73)       *WIF1*     12            63755986    0.315893774
  rs7397906    1.48E-01    0.90( 0.78--1.04)       *WIF1*     12            63769889    0.270394908
  rs7309476    1.43E-01    1.11( 0.96--1.29)       *WIF1*     12            63773962    0.270394908
  rs1466828    1.59E-01    0.79( 0.56--1.10)       *WIF1*     12            63790221    0.270394908
  rs17101044   5.78E-01    1.08( 0.82--1.42)       *WIF1*     12            63791366    0.392545122
  rs7301320    2.72E-03    1.35( 1.11--1.65)       *WIF1*     12            63800533    0.100176561
  rs17101051   4.36E-01    0.91( 0.72--1.15)       *WIF1*     12            63803872    0.359395383
  rs2336434    5.44E-01    0.87( 0.55--1.37)       *WIF1*     12            63805533    0.379736909
  rs17101056   5.14E-01    0.92( 0.72--1.18)       *WIF1*     12            63806743    0.377760052
  rs7304867    6.68E-02    0.61( 0.36--1.03)       *WIF1*     12            63806806    0.217115370
  rs10878232   2.16E-03    1.36( 1.12--1.66)       *WIF1*     12            63808914    0.095602299
  rs1155722    6.21E-03    1.32( 1.08--1.61)       *WIF1*     12            63809424    0.135500153
  rs12318130   3.98E-01    1.12( 0.86--1.47)       *WIF1*     12            63810846    0.349296428
  rs6946781    2.87E-02    0.63( 0.42--0.95)       *WNT2*     7             116694979   0.176207503
  rs887574     3.59E-01    1.08( 0.92--1.27)       *WNT2*     7             116703248   0.328827360
  rs887575     1.59E-01    0.91( 0.79--1.04)       *WNT2*     7             116703464   0.270394908
  rs4730775    8.60E-02    1.23( 0.97--1.56)       *WNT2*     7             116704354   0.244482539
  rs2228946    6.25E-01    0.95( 0.78--1.16)       *WNT2*     7             116705321   0.410945313
  rs733153     8.63E-01    1.02( 0.80--1.31)       *WNT2*     7             116706028   0.463958815
  rs2896218    2.29E-01    0.88( 0.72--1.08)       *WNT2*     7             116707214   0.296677764
  rs3779548    5.15E-01    1.05( 0.91--1.20)       *WNT2*     7             116718131   0.377760052
  rs17139625   6.60E-01    0.94( 0.73--1.22)       *WNT2*     7             116722714   0.420006663
  rs39306      2.32E-01    0.89( 0.73--1.08)       *WNT2*     7             116728472   0.296677764
  rs6947329    4.41E-02    1.29( 1.01--1.65)       *WNT2*     7             116730371   0.186200636
  rs1989836    1.87E-01    0.87( 0.72--1.07)       *WNT2*     7             116734432   0.284431004
  rs2285545    3.44E-02    0.87( 0.76--0.99)       *WNT2*     7             116735407   0.186192568
  rs2239956    9.43E-02    1.26( 0.96--1.64)       *WNT2*     7             116736522   0.246983910
  rs739517     1.85E-01    0.83( 0.63--1.09)       *WNT2*     7             116742935   0.284431004
  rs39315      1.71E-01    0.90( 0.78--1.04)       *WNT2*     7             116750798   0.277576313
  rs254536     1.65E-01    0.87( 0.71--1.06)       *WNT2*     7             116757818   0.274758970
  rs6961545    8.37E-01    0.97( 0.74--1.28)       *WNT2*     7             116759067   0.452937961
  rs254538     2.56E-01    0.89( 0.74--1.08)       *WNT2*     7             116760524   0.302008524
  rs3795821    1.84E-01    0.87( 0.71--1.07)       *WNT2B*    1             112802088   0.284431004
  rs2488787    2.02E-01    0.91( 0.78--1.05)       *WNT2B*    1             112807331   0.284431004
  rs1175649    8.69E-01    0.98( 0.75--1.27)       *WNT2B*    1             112820800   0.465726073
  rs1175650    1.10E-01    0.83( 0.67--1.04)       *WNT2B*    1             112821097   0.247221759
  rs10776751   7.01E-01    1.06( 0.80--1.39)       *WNT2B*    1             112821821   0.426046532
  rs1620668    8.45E-01    1.02( 0.83--1.26)       *WNT2B*    1             112825503   0.456546450
  rs974442     4.02E-01    0.90( 0.72--1.14)       *WNT2B*    1             112829794   0.349296428
  rs351359     6.62E-01    1.05( 0.85--1.29)       *WNT2B*    1             112841800   0.420006663
  rs351360     1.58E-01    0.83( 0.64--1.08)       *WNT2B*    1             112841944   0.270394908
  rs11807828   4.69E-01    1.11( 0.84--1.47)       *WNT2B*    1             112844072   0.360602406
  rs351361     9.30E-01    0.99( 0.81--1.22)       *WNT2B*    1             112844081   0.478174891
  rs351364     5.23E-01    1.12( 0.79--1.59)       *WNT2B*    1             112846584   0.379736909
  rs3790604    1.59E-01    0.81( 0.60--1.09)       *WNT2B*    1             112848402   0.270394908
  rs3790606    3.47E-01    0.91( 0.74--1.11)       *WNT2B*    1             112853709   0.328827360
  rs351370     5.38E-01    1.08( 0.84--1.38)       *WNT2B*    1             112856182   0.379736909
  rs3790609    3.51E-01    1.11( 0.89--1.37)       *WNT2B*    1             112858513   0.328827360
  rs2273368    2.62E-01    1.13( 0.91--1.39)       *WNT2B*    1             112865294   0.306380050
  rs3790611    1.58E-01    0.89( 0.75--1.05)       *WNT2B*    1             112869315   0.270394908
  rs3809857    3.48E-02    0.80( 0.65--0.98)       *WNT3*     17            42203482    0.186192568
  rs199506     9.52E-01    0.99( 0.81--1.23)       *WNT3*     17            42214192    0.481138076
  rs199500     6.37E-01    0.95( 0.77--1.17)       *WNT3*     17            42218572    0.414986215
  rs2074404    2.46E-01    1.28( 0.84--1.94)       *WNT3*     17            42220599    0.301906315
  rs2074405    2.55E-01    1.10( 0.93--1.31)       *WNT3*     17            42221161    0.302008524
  rs199497     7.89E-01    1.03( 0.82--1.29)       *WNT3*     17            42221762    0.443413702
  rs199496     3.51E-01    1.12( 0.89--1.41)       *WNT3*     17            42221887    0.328827360
  rs11658976   1.22E-02    1.45( 1.08--1.94)       *WNT3*     17            42221965    0.142078914
  rs12452064   1.98E-01    1.17( 0.92--1.50)       *WNT3*     17            42223353    0.284431004
  rs199494     2.77E-01    1.15( 0.89--1.47)       *WNT3*     17            42224229    0.310012797
  rs7218567    4.29E-03    1.68( 1.18--2.40)       *WNT3*     17            42225421    0.128006452
  rs8080199    1.92E-01    1.17( 0.93--1.47)       *WNT3*     17            42228781    0.284431004
  rs11650531   1.21E-01    0.87( 0.74--1.04)       *WNT3*     17            42229159    0.254403903
  rs1563304    8.83E-01    1.02( 0.81--1.28)       *WNT3*     17            42229617    0.469718466
  rs7207916    2.06E-01    0.83( 0.62--1.11)       *WNT3*     17            42234514    0.284431004
  rs3933652    5.34E-01    1.07( 0.86--1.34)       *WNT3*     17            42243714    0.379736909
  rs3933653    3.68E-01    0.82( 0.54--1.26)       *WNT3*     17            42243741    0.331747799
  rs3916033    7.70E-01    1.03( 0.84--1.27)       *WNT3*     17            42244702    0.442803211
  rs11079738   3.37E-01    0.90( 0.73--1.11)       *WNT3*     17            42259048    0.328827360
  rs708108     1.05E-01    1.18( 0.97--1.45)       *WNT3A*    1             226256478   0.247221759
  rs708110     2.73E-02    1.26( 1.03--1.55)       *WNT3A*    1             226257428   0.175417920
  rs708122     4.29E-01    0.92( 0.75--1.13)       *WNT3A*    1             226283620   0.359395383
  rs10916258   1.74E-01    0.87( 0.71--1.06)       *WNT3A*    1             226286505   0.278295542
  rs3121309    7.14E-01    1.08( 0.72--1.61)       *WNT3A*    1             226289659   0.426046532
  rs3121310    1.47E-02    1.39( 1.07--1.82)       *WNT3A*    1             226291447   0.144627899
  rs7412010    3.83E-01    1.11( 0.88--1.40)       *WNT4*     1             22309033    0.338387524
  rs4654783    1.77E-02    1.58( 1.08--2.31)       *WNT4*     1             22312107    0.144627899
  rs3765351    1.82E-01    1.19( 0.92--1.52)       *WNT4*     1             22318578    0.284431004
  rs12131703   7.04E-01    0.96( 0.77--1.20)       *WNT4*     1             22320804    0.426046532
  rs7526484    4.59E-01    0.93( 0.76--1.14)       *WNT4*     1             22324432    0.359705483
  rs10917155   7.32E-03    1.54( 1.12--2.11)       *WNT4*     1             22324553    0.135500153
  rs2235525    5.44E-01    0.93( 0.75--1.16)       *WNT4*     1             22326912    0.379736909
  rs10917158   5.44E-01    0.93( 0.75--1.16)       *WNT4*     1             22326960    0.379736909
  rs2865174    9.04E-01    0.98( 0.71--1.35)       *WNT4*     1             22337747    0.475872051
  rs7515106    2.09E-02    1.61( 1.07--2.42)       *WNT4*     1             22345997    0.149155672
  rs7521775    9.31E-02    1.24( 0.96--1.60)       *WNT4*     1             22348236    0.246983910
  rs7542242    2.66E-01    1.12( 0.92--1.37)       *WNT4*     1             22350080    0.307524913
  rs7548239    8.34E-01    1.05( 0.68--1.60)       *WNT4*     1             22351780    0.452520518
  rs1499890    9.62E-02    0.89( 0.78--1.02)       *WNT5A*    3             55464838    0.247172881
  rs629537     1.95E-02    1.29( 1.04--1.60)       *WNT5A*    3             55466053    0.146727575
  rs503022     3.62E-02    1.26( 1.01--1.56)       *WNT5A*    3             55466476    0.186192568
  rs508407     1.08E-01    1.22( 0.96--1.57)       *WNT5A*    3             55467460    0.247221759
  rs476986     8.01E-01    0.94( 0.60--1.49)       *WNT5A*    3             55468554    0.445017693
  rs11706227   7.94E-01    1.03( 0.82--1.31)       *WNT5A*    3             55471300    0.443989861
  rs597437     2.72E-02    1.43( 1.04--1.95)       *WNT5A*    3             55471449    0.175417920
  rs11710229   6.22E-01    1.06( 0.84--1.34)       *WNT5A*    3             55472993    0.410413148
  rs590386     9.43E-02    1.22( 0.97--1.54)       *WNT5A*    3             55474447    0.246983910
  rs1047898    8.53E-02    0.89( 0.78--1.02)       *WNT5A*    3             55474821    0.244482539
  rs1829556    1.33E-01    0.90( 0.79--1.03)       *WNT5A*    3             55476215    0.263342145
  rs7622120    6.52E-02    0.79( 0.61--1.02)       *WNT5A*    3             55479770    0.214878269
  rs11918967   4.30E-01    1.10( 0.87--1.40)       *WNT5A*    3             55480430    0.359395383
  rs648872     1.93E-01    1.15( 0.93--1.42)       *WNT5A*    3             55494897    0.284431004
  rs566926     2.11E-01    0.90( 0.77--1.06)       *WNT5A*    3             55495818    0.284945038
  rs557077     4.73E-02    1.40( 1.00--1.96)       *WNT5A*    3             55506307    0.186667333
  rs4765829    1.55E-01    0.87( 0.71--1.06)       *WNT5B*    12            1591055     0.270394908
  rs10773974   2.69E-01    0.90( 0.74--1.09)       *WNT5B*    12            1619633     0.307820239
  rs2270038    1.69E-01    0.90( 0.78--1.05)       *WNT5B*    12            1620166     0.277576313
  rs2240509    2.84E-01    0.88( 0.70--1.11)       *WNT5B*    12            1620858     0.312911216
  rs2240510    2.85E-01    0.83( 0.59--1.17)       *WNT5B*    12            1623486     0.312911216
  rs2240511    1.77E-01    0.86( 0.69--1.07)       *WNT5B*    12            1623551     0.279313968
  rs7132752    8.10E-01    0.96( 0.69--1.34)       *WNT5B*    12            1623995     0.447606546
  rs3803164    1.76E-01    0.87( 0.72--1.06)       *WNT5B*    12            1625915     0.279313968
  rs3803163    2.72E-01    0.83( 0.60--1.15)       *WNT5B*    12            1626221     0.308376026
  rs12819505   1.37E-03    1.58( 1.19--2.09)       *WNT5B*    12            1626926     0.095030240
  rs1003939    9.87E-03    0.56( 0.36--0.87)       *WNT5B*    12            1626939     0.135500153
  rs6489314    8.65E-02    0.82( 0.66--1.03)       *WNT5B*    12            1627431     0.244482539
  rs4766403    1.03E-02    1.21( 1.05--1.39)       *WNT5B*    12            1630739     0.135500153
  rs4766408    3.50E-01    0.91( 0.74--1.11)       *WNT5B*    12            1634790     0.328827360
  rs7296858    1.71E-01    1.21( 0.92--1.59)       *WNT5B*    12            1636194     0.277576313
  rs7596898    4.86E-02    0.80( 0.64--1.00)       *WNT6*     2             219427976   0.188401227
  rs940469     2.50E-01    1.13( 0.92--1.39)       *WNT6*     2             219428221   0.301906315
  rs751135     6.56E-01    1.04( 0.88--1.22)       *WNT6*     2             219428593   0.418665386
  rs690877     3.43E-01    1.10( 0.90--1.35)       *WNT6*     2             219430908   0.328827360
  rs2053101    6.88E-01    0.92( 0.62--1.38)       *WNT7A*    3             13825667    0.424838822
  rs9864832    9.03E-03    1.52( 1.11--2.08)       *WNT7A*    3             13827744    0.135500153
  rs11712819   3.55E-01    0.91( 0.75--1.11)       *WNT7A*    3             13830800    0.328827360
  rs2163910    7.99E-01    1.03( 0.81--1.31)       *WNT7A*    3             13832893    0.445017693
  rs1124480    5.25E-01    0.93( 0.73--1.17)       *WNT7A*    3             13832970    0.379736909
  rs1946620    1.10E-02    1.32( 1.07--1.63)       *WNT7A*    3             13833800    0.135500153
  rs3796316    5.08E-01    1.09( 0.85--1.39)       *WNT7A*    3             13834174    0.377760052
  rs3796314    3.09E-01    1.12( 0.90--1.38)       *WNT7A*    3             13834333    0.315893774
  rs9840696    3.33E-01    0.90( 0.73--1.11)       *WNT7A*    3             13840076    0.328827360
  rs12492620   4.02E-01    0.92( 0.75--1.13)       *WNT7A*    3             13842256    0.349296428
  rs867606     5.24E-01    1.07( 0.86--1.33)       *WNT7A*    3             13844302    0.379736909
  rs934453     6.91E-01    0.95( 0.75--1.21)       *WNT7A*    3             13845053    0.424838822
  rs12634816   1.37E-01    1.29( 0.92--1.81)       *WNT7A*    3             13847271    0.263578639
  rs11711182   1.21E-01    1.19( 0.95--1.49)       *WNT7A*    3             13851910    0.254403903
  rs12634112   4.59E-01    0.92( 0.73--1.15)       *WNT7A*    3             13853890    0.359705483
  rs11922919   5.87E-01    1.06( 0.86--1.30)       *WNT7A*    3             13854617    0.396598092
  rs9863149    2.71E-01    1.18( 0.88--1.58)       *WNT7A*    3             13858361    0.308376026
  rs4257529    5.13E-01    1.07( 0.87--1.32)       *WNT7A*    3             13869117    0.377760052
  rs3762721    5.52E-01    0.93( 0.73--1.18)       *WNT7A*    3             13870807    0.383590947
  rs12639607   3.62E-01    1.11( 0.89--1.38)       *WNT7A*    3             13871285    0.328827360
  rs9819887    4.33E-01    1.06( 0.91--1.24)       *WNT7A*    3             13873619    0.359395383
  rs13069140   1.98E-01    0.84( 0.64--1.10)       *WNT7A*    3             13878304    0.284431004
  rs6442416    1.34E-01    0.90( 0.78--1.03)       *WNT7A*    3             13882101    0.263342145
  rs9864031    2.02E-01    0.87( 0.71--1.08)       *WNT7A*    3             13883072    0.284431004
  rs12632968   2.51E-01    0.92( 0.80--1.06)       *WNT7A*    3             13887198    0.301906315
  rs4685048    4.71E-01    0.95( 0.82--1.09)       *WNT7A*    3             13897736    0.360699651
  rs1077524    6.70E-01    0.96( 0.79--1.17)       *WNT7A*    3             13905134    0.422621937
  rs6768050    8.13E-02    1.29( 0.97--1.72)       *WNT7A*    3             13905491    0.239365623
  rs217259     4.45E-01    1.14( 0.82--1.58)       *WNT8A*    5             137440862   0.359705483
  rs10440755   2.94E-01    0.88( 0.70--1.11)       *WNT8A*    5             137442365   0.315417003
  rs4835761    6.94E-01    1.05( 0.82--1.34)       *WNT8A*    5             137445768   0.424838822
  rs10036244   5.82E-01    0.94( 0.77--1.16)       *WNT8A*    5             137447624   0.394635311
  rs2040862    3.75E-01    1.10( 0.89--1.35)       *WNT8A*    5             137447888   0.333860360
  rs4919464    1.49E-01    0.89( 0.75--1.04)       *WNT8B*    10            102211185   0.270394908
  rs3793771    1.15E-01    0.88( 0.74--1.03)       *WNT8B*    10            102212947   0.247366510
  rs12762598   8.24E-01    1.02( 0.87--1.20)       *WNT8B*    10            102217746   0.450428119
  rs7552818    9.03E-01    1.01( 0.82--1.25)       *WNT9A*    1             226167514   0.475872051
  rs10916243   2.01E-01    1.10( 0.95--1.28)       *WNT9A*    1             226167742   0.284431004
  rs1009658    1.10E-01    0.84( 0.68--1.04)       *WNT9A*    1             226170404   0.247221759
  rs12748472   2.78E-02    1.18( 1.02--1.38)       *WNT9A*    1             226170998   0.175417920
  rs8192633    9.90E-01    1.00( 0.62--1.59)       *WNT9A*    1             226176094   0.495714725
  rs10127943   1.27E-01    1.17( 0.96--1.43)       *WNT9A*    1             226176687   0.259279357
  rs12046421   7.15E-01    0.96( 0.79--1.18)       *WNT9A*    1             226177357   0.426046532
  rs680997     1.48E-01    0.79( 0.57--1.09)       *WNT9A*    1             226193850   0.270394908
  rs680148     4.05E-02    1.25( 1.01--1.54)       *WNT9A*    1             226194014   0.186192568
  rs681239     5.30E-01    0.89( 0.61--1.29)       *WNT9A*    1             226206295   0.379736909
  rs6665129    2.53E-01    0.87( 0.69--1.10)       *WNT9A*    1             226207083   0.301906315
  rs2083798    9.16E-01    0.99( 0.81--1.21)       *WNT9B*    17            42276896    0.475872051
  rs2083797    4.03E-01    1.14( 0.84--1.54)       *WNT9B*    17            42276928    0.349470404
  rs4968275    9.42E-01    1.01( 0.81--1.25)       *WNT9B*    17            42279659    0.478174891
  rs7212246    9.42E-01    1.01( 0.81--1.25)       *WNT9B*    17            42280490    0.478174891
  rs12150651   7.07E-01    0.96( 0.77--1.19)       *WNT9B*    17            42288568    0.426046532
  rs2165846    2.48E-01    1.15( 0.91--1.47)       *WNT9B*    17            42296365    0.301906315
  rs12952746   4.35E-01    1.10( 0.87--1.39)       *WNT9B*    17            42298412    0.359395383
  rs6504591    3.06E-01    0.93( 0.81--1.07)       *WNT9B*    17            42299827    0.315893774
  rs4968281    4.42E-01    1.16( 0.79--1.71)       *WNT9B*    17            42305121    0.359705483
  rs1530364    4.45E-02    0.67( 0.45--0.99)       *WNT9B*    17            42306776    0.186200636
  rs754474     2.52E-01    1.24( 0.86--1.78)       *WNT9B*    17            42308855    0.301906315
  rs17603901   8.32E-01    1.03( 0.79--1.34)       *WNT9B*    17            42313021    0.452520518
  rs10177996   7.78E-01    1.03( 0.83--1.28)       *WNT10A*   2             219454805   0.443413702
  rs4574113    7.12E-01    1.04( 0.84--1.30)       *WNT10A*   2             219470906   0.426046532
  rs833839     4.98E-01    1.08( 0.86--1.35)       *WNT10B*   12            47653157    0.377760052
  rs7311091    4.72E-01    1.11( 0.84--1.46)       *WNT10B*   12            47669474    0.360699651
  rs664499     3.06E-01    0.86( 0.65--1.15)       *WNT11*    11            75565334    0.315893774
  rs626207     2.39E-01    1.13( 0.92--1.38)       *WNT11*    11            75565460    0.301281403
  rs4944091    8.02E-01    0.97( 0.78--1.21)       *WNT11*    11            75566622    0.445017693
  rs647159     2.64E-01    1.18( 0.88--1.57)       *WNT11*    11            75570389    0.307231178
  rs11236644   3.62E-01    0.94( 0.81--1.08)       *WNT11*    11            75572655    0.328827360
  rs581794     6.45E-01    0.95( 0.75--1.19)       *WNT11*    11            75572939    0.415574805
  rs12277860   4.39E-01    0.91( 0.73--1.15)       *WNT11*    11            75574295    0.359395383
  rs17749202   4.67E-02    1.39( 1.00--1.92)       *WNT11*    11            75575022    0.186667333
  rs7936750    2.15E-01    0.81( 0.57--1.13)       *WNT11*    11            75577055    0.284945038
  rs10899175   1.02E-01    1.20( 0.96--1.50)       *WNT11*    11            75577129    0.247221759
  rs882151     7.14E-01    0.96( 0.78--1.18)       *WNT11*    11            75581785    0.426046532
  rs3781730    5.45E-01    1.07( 0.86--1.33)       *WNT11*    11            75585731    0.379736909
  rs689095     1.63E-01    0.87( 0.71--1.06)       *WNT11*    11            75591735    0.273188390
  rs663907     2.31E-01    0.84( 0.63--1.12)       *WNT11*    11            75600717    0.296677764
  rs689419     7.88E-01    0.97( 0.79--1.19)       *WNT11*    11            75604615    0.443413702
  rs12416814   3.74E-01    1.23( 0.78--1.92)       *WNT11*    11            75605089    0.333860360
  rs3757552    5.68E-01    0.93( 0.72--1.20)       *WNT16*    7             120751201   0.388647584
  rs3801387    1.52E-01    1.15( 0.95--1.40)       *WNT16*    7             120762001   0.270394908
  rs3801385    7.16E-01    1.05( 0.80--1.37)       *WNT16*    7             120764779   0.426046532
  rs2707461    2.06E-01    0.77( 0.51--1.16)       *WNT16*    7             120774586   0.284431004
  rs2536182    1.30E-01    0.90( 0.78--1.03)       *WNT16*    7             120778073   0.263051430

###### 

Wnt pathway SNPs associated with survival in multivariate analysis in cohort 1 (P\<0.05)[\*](#TFN3){ref-type="table-fn"}

  SNP          *P* value   Hazard Ratio (95% CI)   Gene      Chromo-some   Position    Q value
  ------------ ----------- ----------------------- --------- ------------- ----------- -------------
  rs11868547   0.0006      0.77 (0.66--0.89)       *AXIN2*   17            60954065    0.095030240
  rs12819505   0.0014      1.58 (1.19--2.09)       *WNT5B*   12            1626926     0.095030240
  rs4541111    0.0015      0.79 (0.68--0.91)       *AXIN2*   17            60965000    0.095030240
  rs4413407    0.0017      1.28 (1.10--1.50)       *CXXC4*   4             105612810   0.095030240
  rs10878232   0.0022      1.36 (1.12--1.66)       *WIF1*    12            63808914    0.095602299
  rs7301320    0.0027      1.35 (1.11--1.65)       *WIF1*    12            63800533    0.100176561
  rs7218567    0.0043      1.68 (1.18--2.40)       *WNT3*    17            42225421    0.128006452
  rs390258     0.0046      1.64 (1.16--2.30)       *TLE2*    19            2947339     0.128006452
  rs7591       0.0061      1.23 (1.06--1.44)       *AXIN2*   17            60955544    0.135500153
  rs1155722    0.0062      1.32 (1.08--1.61)       *WIF1*    12            63809424    0.135500153
  rs10917155   0.0073      1.54 (1.12--2.11)       *WNT4*    1             22324553    0.135500153
  rs9864832    0.0090      1.52 (1.11--2.08)       *WNT7A*   3             13827744    0.135500153
  rs4988300    0.0098      0.74 (0.58--0.93)       *LRP5*    11            67845407    0.135500153
  rs1003939    0.0099      0.56 (0.36--0.87)       *WNT5B*   12            1626939     0.135500153
  rs4766403    0.010       1.21 (1.05--1.39)       *WNT5B*   12            1630739     0.135500153
  rs2508836    0.010       0.81 (0.68--0.95)       *LRP5*    11            67847841    0.135500153
  rs1012672    0.011       1.47 (1.09--1.97)       *LRP6*    12            12176182    0.135500153
  rs1946620    0.011       1.32 (1.07--1.63)       *WNT7A*   3             13833800    0.135500153
  rs11658976   0.012       1.45 (1.08--1.94)       *WNT3*    17            42221965    0.142078914
  rs12469777   0.014       0.85 (0.74--0.97)       *FRZB*    2             183440609   0.144627899
  rs3121310    0.015       1.39 (1.07--1.82)       *WNT3A*   1             226291447   0.144627899
  rs11655966   0.015       1.21 (1.04--1.41)       *AXIN2*   17            60960112    0.144627899
  rs12942924   0.016       1.18 (1.03--1.36)       *AXIN2*   17            60996861    0.144627899
  rs11079571   0.016       1.29 (1.05--1.59)       *AXIN2*   17            60979143    0.144627899
  rs11054760   0.017       1.53 (1.08--2.17)       *LRP6*    12            12320749    0.144627899
  rs11919795   0.018       0.67 (0.48--0.93)       *DVL3*    3             185373562   0.144627899
  rs4654783    0.018       1.58 (1.08--2.31)       *WNT4*    1             22312107    0.144627899
  rs629537     0.020       1.29 (1.04--1.60)       *WNT5A*   3             55466053    0.146727575
  rs314756     0.020       0.69 (0.51--0.94)       *LRP5*    11            67868248    0.146727575
  rs713065     0.020       0.79 (0.64--0.96)       *FZD4*    11            86335168    0.146727575
  rs7515106    0.021       1.61 (1.07--2.42)       *WNT4*    1             22345997    0.149155672
  rs423232     0.022       0.74 (0.57--0.96)       *TLE2*    19            2947483     0.152312051
  rs597437     0.027       1.43 (1.04--1.95)       *WNT5A*   3             55471449    0.17541792
  rs708110     0.027       1.26 (1.03--1.55)       *WNT3A*   1             226257428   0.17541792
  rs12748472   0.028       1.18 (1.02--1.38)       *WNT9A*   1             226170998   0.17541792
  rs6946781    0.029       0.63 (0.42--0.95)       *WNT2*    7             116694979   0.176207503
  rs9888749    0.031       0.76 (0.60--0.98)       *AXIN1*   16            348373      0.185653186
  rs64388      0.033       1.25 (1.02--1.52)       *LRP5*    11            67830957    0.186192568
  rs7224837    0.034       1.28 (1.02--1.62)       *AXIN2*   17            60958585    0.186192568
  rs2285545    0.034       0.87 (0.76--0.99)       *WNT2*    7             116735407   0.186192568
  rs3809857    0.035       0.80 (0.65--0.98)       *WNT3*    17            42203482    0.186192568
  rs503022     0.036       1.26 (1.01--1.56)       *WNT5A*   3             55466476    0.186192568
  rs1548581    0.037       1.29 (1.02--1.64)       *AXIN2*   17            60995973    0.186192568
  rs7359414    0.037       0.78 (0.61--0.99)       *AXIN1*   16            302639      0.186192568
  rs312786     0.038       0.66 (0.45--0.98)       *LRP5*    11            67876553    0.186192568
  rs214246     0.040       0.77 (0.61--0.99)       *AXIN1*   16            289294      0.186192568
  rs4698921    0.040       1.16 (1.01--1.34)       *CXXC4*   4             105633671   0.186192568
  rs680148     0.041       1.25 (1.01--1.54)       *WNT9A*   1             226194014   0.186192568
  rs676318     0.042       0.75 (0.57--0.99)       *LRP5*    11            67973996    0.186192568
  rs10431302   0.042       0.80 (0.65--0.99)       *LRP6*    12            12320918    0.186192568
  rs6947329    0.044       1.29 (1.01--1.65)       *WNT2*    7             116730371   0.186200636
  rs1530364    0.045       0.67 (0.45--0.99)       *WNT9B*   17            42306776    0.186200636
  rs3781586    0.045       1.26 (1.01--1.57)       *LRP5*    11            67955969    0.186200636
  rs17749202   0.047       1.39 (1.00--1.92)       *WNT11*   11            75575022    0.186667333
  rs4074947    0.047       1.23 (1.00--1.51)       *AXIN2*   17            60957682    0.186667333
  rs557077     0.047       1.40 (1.00--1.96)       *WNT5A*   3             55506307    0.186667333
  rs7596898    0.049       0.80 (0.64--1.00)       *WNT6*    2             219427976   0.188401227

Adjusted for age, race, sex, pack-year smoking, clinical stage, and performance status

###### 

Wnt pathway SNPs with q\<0.10 in cohort 1

  SNP          Gene      Location      Allelic change   Minor Allele Frequency   Model      Hazard Ratio[\*](#TFN4){ref-type="table-fn"} (95% CI)   *P* value   q value
  ------------ --------- ------------- ---------------- ------------------------ ---------- ------------------------------------------------------- ----------- ---------
  rs11868547   *AXIN2*   3′ flanking   G\>C             0.421                    Additive   0.77 (0.66--0.89)                                       6.10E-04    0.09503
  rs12819505   *WNT5B*   3′ flanking   A\>G             0.07                     Dominant   1.58 (1.19--2.09)                                       1.37E-03    0.09503
  rs4541111    *AXIN2*   Intron        C\>A             0.456                    Additive   0.79 (0.68--0.91)                                       1.53E-03    0.09503
  rs4413407    *CXXC4*   3′ UTR        G\>A             0.299                    Additive   1.28 (1.10--1.50)                                       1.72E-03    0.09503
  rs10878232   *WIF1*    5′ flanking   A\>C             0.242                    Dominant   1.36 (1.12--1.66)                                       2.16E-03    0.09560

Adjusted for age, race, sex, pack-year smoking, clinical stage, and performance status

###### 

Impact of number of unfavorable genotypes on survival in cohort 1

  No. unfavorable genotypes   No. (%) alive   No. (%) dead   Hazard ratio (95% CI) (1 SNP = reference)   *P* value      Median Survival Time (mo.)   Log-rank p value
  --------------------------- --------------- -------------- ------------------------------------------- -------------- ---------------------------- ------------------
  1                           19 (46.3)       22 (53.7)                                                                 19.67                        
  2                           83 (26.9)       226 (73.1)     1.53 (0.97--2.41)                           6.8 × 10^−2^   15.56                        
  3--5                        40 (16.1)       208 (83.9)     2.61 (1.65--4.12)                           4.3 × 10^−5^   10.72                        1.9 × 10^−7^
  trend                                                                                                  3.8 × 10^−9^                                

###### 

Minor Allele Frequency by race for SNPs significantly associated with patient survival

  SNP          All    White   Black   Other
  ------------ ------ ------- ------- -------
  rs11868547   0.44   0.45    0.20    0.56
  rs12819505   0.07   0.08    0.01    0.04
  rs4541111    0.47   0.49    0.20    0.54
  rs4413407    0.30   0.32    0.05    0.33
  rs10878232   0.28   0.28    0.33    0.27

###### 

Hazard ratios and median survival times for different recursive partitioning nodes in cohort 1

  ---------------------------------------------------------------------------------------------------------------------------------
  STREE Nodes   Dead\         Alive\       Adjusted Hazard Ratio (95% CI)   *P* value    Median Survival (months)   Log Rank Test
                N (%)         N (%)                                                                                 
  ------------- ------------- ------------ -------------------------------- ------------ -------------------------- ---------------
  1             34 (69.39)    15 (30.61)   1.00 (reference)                 18.82                                   

  2             192 (69.82)   83 (30.18)   1.09 (0.73--1.62)                0.067        17.27                      

  3             163 (82.32)   35 (17.68)   1.93 (1.30--2.89)                0.001        10.07                      

  4             39 (86.67)    6 (13.33)    1.79 (1.08--2.96)                0.024        13.52                      

  5             28 (90.32)    3(9.68)      1.98 (1.17--3.37)                0.011        11.94                      2.68 × 10^−6^

  STREE Group                                                                                                       

  Nodes 1\~2    226 (69.75)   98 (30.25)   1.00 (reference)                 17.27                                   

  Nodes 3\~5    230 (83.94)   44 (16.06)   1.78 (1.46--2.17)                1 × 10^−8^   11.09                      4.66 × 10^−8^
  ---------------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of patients assessed in cohorts 2, 3 and 4

  -------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                      Cohort 2\                               Cohort 3\          Cohort 4\
                                                                No. Patients (%)                        No. Patients (%)   No. Patients (%)
  ------------------------------------------------------------- --------------------------------------- ------------------ ------------------
  Median survival, months                                       21.09                                   118.3              86.05

  Median age (range), years                                     64.02[\*](#TFN5){ref-type="table-fn"}   63 (29--83)        67 (34--86)

  Pack year, median (range)[\*\*](#TFN6){ref-type="table-fn"}   40.48[\*](#TFN5){ref-type="table-fn"}   40 (0.1--159)      45 (0.2--256)

  Survival status at last follow-up                                                                                        

   Alive                                                        49                                      88                 210

   Dead                                                         191                                     39                 130

  Sex                                                                                                                      

   Male                                                         142                                     68                 166

   Female                                                       98                                      59                 174

  Clinical stage                                                                                                           

   Stage IA                                                                                             23                 181

   Stage IB                                                                                             55                 113

   Stage IIA                                                                                            14                 10

   Stage IIB                                                                                            35                 36

   Stage III                                                    106                                                        

   Stage IV                                                     134                                                        

  Smoking status                                                                                                           

   Never                                                        14                                      16                 48

   Former                                                       150                                     67                 168

   Current & Recently Quit (\<1 year)                           76                                      44                 124

  ECOG Performance status                                                                                                  

   0                                                            64                                                         

   1                                                            120                                                        

   2--4                                                         13                                                         

  Tumor Type                                                                                                               

   Adenocarcinoma                                                                                       74                 213

   Squamous                                                                                             34                 87

   NSCLC not otherwise specified                                                                        7                  11

   Other                                                                                                12                 29

  Race                                                                                                                     

   White                                                                                                109                305

   Black                                                                                                10                 25

   Others                                                                                               8                  10

  Treatment                                                                                                                

   Chemotherapy (platinum regimen) only                         100                                                        

   Platinum regimen + radiotherapy                              140                                                        

   Surgery + adjuvant platinum regimen                                                                  127                

   Surgery alone                                                                                                           340
  -------------------------------------------------------------------------------------------------------------------------------------------

mean instead of median; range not available

among ever smokers

###### 

Assessment of SNPs in secondary analyses (cohorts 2--4)

  SNP          Mayo Clinic (Cohort 2)[†](#TFN8){ref-type="table-fn"}   MDACC Adjuvant Chemo (Cohort 3)[‡](#TFN9){ref-type="table-fn"}   MDACC Surgery Alone (Cohort 4)[‡](#TFN9){ref-type="table-fn"}   Mayo + Adjuvant (Cohorts 2 + 3)   Mayo + Adjuvant + Surgery (Cohorts 2 + 3 + 4)                                                                     
  ------------ ------------------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------- --------------------------------- ----------------------------------------------- ------ ------------------ ------ ------ ------------------ ------ ------
  rs11868547   0.94(0.75--1.18)                                        0.58                                                             0.89(0.55--1.45)                                                0.65                              0.96( 0.74--1.24)                               0.75   0.93(0.76--1.14)   0.48   0.85   0.94(0.80--1.11)   0.46   0.96
  rs12819505   1.30(0.85--1.99)                                        0.23                                                             0.40(0.14--1.18)                                                0.10                              1.12( 0.67--1.86)                               0.68   0.80(0.26--2.50)   0.70   0.04   1.11(0.81--1.52)   0.51   0.13
  rs4413407    0.88(0.69--1.13)                                        0.32                                                             1.10(0.61--2.01)                                                0.75                              0.99( 0.76--1.30)                               0.96   0.91(0.72--1.15)   0.43   0.50   0.94(0.79--1.13)   0.52   0.72
  rs10878232   1.00(0.77--1.28)                                        0.98                                                             1.80(0.91--3.56)                                                0.09                              1.05( 0.79--1.41)                               0.73   1.07(0.85--1.36)   0.58   0.11   1.06(0.88--1.28)   0.52   0.28

P-H: *P* value for heterogeneity

Advanced stage patients

Early stage patients
